Key Takeaways
- Shares of uniQure (QURE) climbed 36% Monday following news that Vinay Prasad will leave the FDA’s Center for Biologics Evaluation and Research
- Prasad had been responsible for regulatory decisions regarding uniQure’s AMT-130, a Huntington’s disease treatment candidate
- RBC Capital lifted its rating on QURE to Outperform from Sector Perform, boosting the price target to $35 from $11
- Gene therapy peers REGENXBIO (RGNX) and Biohaven (BHVN) jumped 13% and 23% respectively
- A Type B meeting between uniQure and the FDA is set for the second quarter of 2026
The past week has delivered dramatic swings for uniQure investors. On March 5, an FDA reviewer openly criticized the biotech company for allegedly “performing a distorted or manipulated comparison” during its phase 1/2 study of AMT-130, a gene therapy for Huntington’s disease. Surprisingly, shares still rallied 18% that session.
The following day, March 6, investors learned that Vinay Prasad, who leads the FDA’s Center for Biologics Evaluation and Research (CBER), plans to depart the agency in April to pursue academic opportunities. QURE shares responded with a 34% surge. By Monday’s close, the total gain reached 36%.
Prasad had been the primary FDA official managing the regulatory review of AMT-130. The agency informed uniQure that approval wouldn’t be granted based on comparisons to natural history data—a stance the company described as a significant “key shift” from previous regulatory guidance established before new FDA management took over.
Additionally, the FDA required uniQure to conduct a comprehensive phase 3 clinical trial, representing a substantial financial and temporal obstacle for a therapy targeting a rare condition.
With Prasad’s announced exit, both Wall Street analysts and market participants have reassessed their outlook. RBC Capital’s Luca Issi elevated QURE to Outperform from Sector Perform while increasing his price objective from $11 to $35. His updated analysis assigns a 50% probability to AMT-130’s eventual regulatory approval.
“We believe that Prasad’s departure is likely to open up a more balanced discussion on risk/reward for HD,” Issi wrote.
Wall Street Weighs In
Stifel’s Paul Matteis characterized Prasad’s departure as “a big win for biotech, especially for companies in the rare disease space.” He highlighted that Prasad had allegedly overturned recommendations from internal FDA scientific review teams to deliver unfavorable decisions on multiple therapeutic candidates.
Truist’s research team observed that Prasad’s leadership “marked a sharp departure from the more flexible regulatory approach for rare and serious diseases” championed by Peter Marks, his predecessor. Several biotechnology companies encountered unexpected regulatory standard changes despite having established prior agreements during early-stage development discussions with the agency, the analysts noted.
The positive sentiment extended beyond uniQure. Other gene therapy developers experienced significant gains, with REGENXBIO (RGNX) advancing 13% and Biohaven (BHVN) climbing 23% on the leadership change.
Looking Ahead for uniQure
uniQure has secured a Type B meeting with FDA regulators scheduled for Q2 2026. This discussion will prove critical as the company seeks clarity on regulatory expectations for AMT-130 moving forward.
Prasad’s official departure from the FDA is expected to occur in April.
Notably, on March 5—the very day public criticism emerged from an FDA official regarding uniQure’s trial methodology—shares still managed an 18% gain, suggesting investors were already factoring in potential changes to regulatory oversight under Prasad’s direction.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
